CytoSorbents (NASDAQ:CTSO) Schedules Q3 2026 Results Announcement and Recent Business Update

Sonal Goyal

30 October 2026 09:16 PM AEDT

CytoSorbents (NASDAQ:CTSO) Schedules Q3 2026 Results Announcement and Recent Business Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

CytoSorbents announced it will report Q3 2026 financial results and provide a Business update to investors.
The company's CytoSorb blood purification device is used in critical care and cardiac surgery applications.
DrugSorb-ATR, targeting anticoagulant removal in cardiac surgery, is a key pipeline and commercialization focus.
The quarterly update will cover clinical, regulatory and commercial developments across the CytoSorb platform.

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy company specializing in blood purification technologies, announced plans to report its third-quarter 2026 financial results and provide a comprehensive business update covering recent clinical, regulatory and commercial developments. The Monmouth Junction, New Jersey-based company develops and markets the CytoSorb blood purification device and the DrugSorb-ATR anticoagulant removal system.

CytoSorb Blood Purification Platform

CytoSorbents' flagship CytoSorb device is an extracorporeal blood purification system used in intensive care and cardiac surgery settings to remove inflammatory mediators, drugs and toxins from the bloodstream. The device is approved in the European Union and a number of other markets for use in critical care conditions including sepsis and cytokine storm, as well as for hemoadsorption during cardiac surgery to manage heparin, anesthetic agents and other drugs. The device is used in high-acuity settings where managing excessive inflammation or drug levels can improve patient outcomes.

In the United States, CytoSorb has been used under Emergency Use Authorization and Expanded Access protocols, while the company's DrugSorb-ATR device — an anticoagulant removal system designed specifically for cardiac surgery patients on direct oral anticoagulants or antiplatelets — has been the primary focus of CytoSorbents' U.S. regulatory strategy. DrugSorb-ATR received FDA Breakthrough Device Designation and has been the subject of clinical development intended to support a U.S. regulatory submission.

Revenue and Commercial Activities

CytoSorbents generates Revenue primarily from sales of CytoSorb devices in Europe and other approved markets, where the product is used in hospital intensive care units and cardiac surgery centers. Revenue trends reflect the pace of new hospital account acquisitions, the frequency of device use per account and the average price per device. European commercial infrastructure and the expansion of the installed account base have been the primary commercial drivers for the company.

U.S. Regulatory and Clinical Development

CytoSorbents' U.S. regulatory strategy centers on DrugSorb-ATR for cardiac surgery patients who are on anticoagulant or antiplatelet therapy prior to surgery. Emergency surgery in patients on these drugs carries elevated bleeding risk, and the ability to remove these drugs rapidly before or during surgery has clear clinical utility. The company's clinical development program for DrugSorb-ATR has been the primary focus of its U.S. clinical investment, with the goal of achieving FDA clearance to commercialize the device in the large U.S. cardiac surgery market.

CytoSorbents enters Q4 2026 with its core CytoSorb commercial business in Europe continuing to generate revenue, while its DrugSorb-ATR U.S. regulatory program represents the primary near-term catalyst for expanding the company's addressable market. The quarterly business update will provide investors with the latest perspective on the company's commercial trajectory and regulatory timeline.

FAQs

Q: What does CytoSorbents do?

A: CytoSorbents develops and markets blood purification technologies including the CytoSorb extracorporeal device for cytokine and drug removal in critical care and cardiac surgery, and DrugSorb-ATR, an anticoagulant removal system for cardiac surgery patients.

Q: What is DrugSorb-ATR?

A: DrugSorb-ATR is CytoSorbents' device designed to rapidly remove direct oral anticoagulants and antiplatelet drugs from patients undergoing emergency or urgent cardiac surgery, reducing bleeding risk. It has received FDA Breakthrough Device Designation.

Q: Where is CytoSorb approved?

A: CytoSorb is approved in the European Union and a number of other markets for use in critical care settings including sepsis management and during cardiac surgery. In the U.S., the company's primary regulatory focus is DrugSorb-ATR.

Q: What was CytoSorbents' Q3 2026 announcement about?

A: CytoSorbents announced it would report Q3 2026 financial results and provide a business update covering recent clinical, regulatory and commercial developments across its blood purification technology platform.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.